A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Analytical Pharmacology Bookmark and Share

Analytical Pharmacology Core Facility (APCF)

The Analytical Pharmacology Core facility (APCF) encourages and facilitiates collaborative research between basic scientists and clinicians by providing a wide range of analytical services that benefit both groups. The APCF conducts pharmacokinetic and pharmacodynamic studies for both chemotherapy clinical trials and peer-reviewed preclinical studies.
 
The primary services of the APCF are:
 
  • Assay development and analysis (LS/MS/MS, GC/MS, HPLC, and AAS) of chemotherapeutic agents and related compounds.
  • Study design and expert analysis of pharmacokinetic, pharmacodynamic, and metabolic data.
 
The facility’s services are available to both City of Hope and external researchers.
 

Research reported in this publication included work performed in the Analytical Pharmacology Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
 

 

Services and Equipment

Services
Services currently offered by the Analytical Pharmacology Core facility:
  • Initial consultation on research projects
  • Study design and protocol review
  • Development, implementation, and validation of analytical methods.
  • Sample analysis (LC/MS/MS, GC/MS, HPLC, and AAS).
  • Pharmacokinetic programming and data analysis
  • Sample acquisition, tracking, and storage. Sample acquisition, storage analysis, including HPLC, LC/MS/MS and GC/MS, and microbiological assay methodologies
  • Participation in collaborative writing

Equipment
Analytical capabilities cover a wide range of available methods including:
  • LC/MC/MS (Waters Quattro Ultima and Quattro Premier XE
  • GC/MS (2 Shimadzu QP-5000's
  • HPLC with UV/Vis, fluorescence, and electrochemical detection (Shimadzu and Thermo Separations)
  • AAS with graphite furnace (PerkinElmer AAnalyst 300

HPLC capability includes four complete systems, which are integrated directly to dedicated computers running EZChrom software for automated post-run analysis. Three of the HPLC systems include automated injection systems for more convenient analysis of a large number of samples.

Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT workstation running MassLynx and QuanLynx software. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated computer running CLASS-5000 software.

In addition to the chromatographic instrumentation, a Perkin Elmer AAnalyst 300 flameless atomic absorption spectrometer (AA) is available for the determination of metals and metal-containing compounds such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated computer.

 

Using the Facility

Scheduling Equipment
To access the Analytical Pharmacology Core facility, investigators should contact Timothy Synold to start the process.

Abstract for Grants

The APCF is located in the Shapiro Building and the analytical equipment is in room 1042. Freezers for sample storage are also located in the Beckman Center Freezer Farm, Room 1012. An additional HPLC with a diode array detector that is used part time for core service activities is located in room 1002 of the Fox North Research Building. HPLC capability includes four complete HPLC systems consisting of seven solvent delivery modules (4 Shimadzu LC-10A's, 2 Shimadzu LC-10AD's, 1 SpectraSystem P4000). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 5100A and 5200A), and photodiode array (SpectraSystem UV6000LP) detection systems. The Shimadzu HPLC systems are integrated directly into one of two dedicated PC's running Shimadzu EZChrom software for automated post-run analysis. Likewise, the SpectraSystem system is integrated to a dedicated PC running Chromquest (OEM version of EZChrom software). Three of the four HPLC systems include automated injection systems (2 Shimadzu SIL-10A's, 1 SpectraSystem AS3000) for more convenient analysis of a large number of samples. A Perkin Elmer AAnalyst 300 AA is available for the determination of metals and metal containing compounds, such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated PC. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software. A Micromass Quattro Ultima API Triple Stage Quadrupole Mass Spectrometer System (LC/MS/MS) provides exquisite selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT Workstation running MassLynx and QuanLynx software. As a result of high demand for LC/MS/.MS services, a second triple quadrupole tandem mass spectrometer (Waters Premier XE) was recently obtained to increase our capabilities. The front-end on the Premier XE is a Waters Agility Ultra-high Pressure Liquid Chromatograph (UPLC) that allows us to maximize sensitivity and minimize run-times, thereby increasing throughput. Like the Quattro Ultima, instrument control and data analysis on the Premier XE is performed with MassLynx and QuanLynx software. In addition, MetaboLynx software was purchased to aid in metabolite identification.

Pricing

Prices and availability vary. PleaseContact Usfor current information.
 
If you are a City of Hope employee, please visitthis core facility's intranet sitefor pricing.
 

Analytical Pharmacology Team

Contact Us

Edward Newman, Ph.D.
Co-director
626-256-HOPE (4673)
enewman@coh.org
 
Timothy W. Synold, Pharm.D.
Co-director
626-256-HOPE (4673)
tsynold@coh.org
 
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000
 
Shapiro Building
Room 1042
Phone: 626-256-HOPE (4673), ext. 62110
Fax: 626-301-8898
 

Analytical Pharmacology

Analytical Pharmacology Core Facility (APCF)

The Analytical Pharmacology Core facility (APCF) encourages and facilitiates collaborative research between basic scientists and clinicians by providing a wide range of analytical services that benefit both groups. The APCF conducts pharmacokinetic and pharmacodynamic studies for both chemotherapy clinical trials and peer-reviewed preclinical studies.
 
The primary services of the APCF are:
 
  • Assay development and analysis (LS/MS/MS, GC/MS, HPLC, and AAS) of chemotherapeutic agents and related compounds.
  • Study design and expert analysis of pharmacokinetic, pharmacodynamic, and metabolic data.
 
The facility’s services are available to both City of Hope and external researchers.
 

Research reported in this publication included work performed in the Analytical Pharmacology Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
 

 

Services and Equipment

Services and Equipment

Services
Services currently offered by the Analytical Pharmacology Core facility:
  • Initial consultation on research projects
  • Study design and protocol review
  • Development, implementation, and validation of analytical methods.
  • Sample analysis (LC/MS/MS, GC/MS, HPLC, and AAS).
  • Pharmacokinetic programming and data analysis
  • Sample acquisition, tracking, and storage. Sample acquisition, storage analysis, including HPLC, LC/MS/MS and GC/MS, and microbiological assay methodologies
  • Participation in collaborative writing

Equipment
Analytical capabilities cover a wide range of available methods including:
  • LC/MC/MS (Waters Quattro Ultima and Quattro Premier XE
  • GC/MS (2 Shimadzu QP-5000's
  • HPLC with UV/Vis, fluorescence, and electrochemical detection (Shimadzu and Thermo Separations)
  • AAS with graphite furnace (PerkinElmer AAnalyst 300

HPLC capability includes four complete systems, which are integrated directly to dedicated computers running EZChrom software for automated post-run analysis. Three of the HPLC systems include automated injection systems for more convenient analysis of a large number of samples.

Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT workstation running MassLynx and QuanLynx software. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated computer running CLASS-5000 software.

In addition to the chromatographic instrumentation, a Perkin Elmer AAnalyst 300 flameless atomic absorption spectrometer (AA) is available for the determination of metals and metal-containing compounds such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated computer.

 

Using the Facility

Using the Facility

Scheduling Equipment
To access the Analytical Pharmacology Core facility, investigators should contact Timothy Synold to start the process.

Abstract for Grants

Abstract for Grants

The APCF is located in the Shapiro Building and the analytical equipment is in room 1042. Freezers for sample storage are also located in the Beckman Center Freezer Farm, Room 1012. An additional HPLC with a diode array detector that is used part time for core service activities is located in room 1002 of the Fox North Research Building. HPLC capability includes four complete HPLC systems consisting of seven solvent delivery modules (4 Shimadzu LC-10A's, 2 Shimadzu LC-10AD's, 1 SpectraSystem P4000). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 5100A and 5200A), and photodiode array (SpectraSystem UV6000LP) detection systems. The Shimadzu HPLC systems are integrated directly into one of two dedicated PC's running Shimadzu EZChrom software for automated post-run analysis. Likewise, the SpectraSystem system is integrated to a dedicated PC running Chromquest (OEM version of EZChrom software). Three of the four HPLC systems include automated injection systems (2 Shimadzu SIL-10A's, 1 SpectraSystem AS3000) for more convenient analysis of a large number of samples. A Perkin Elmer AAnalyst 300 AA is available for the determination of metals and metal containing compounds, such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated PC. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software. A Micromass Quattro Ultima API Triple Stage Quadrupole Mass Spectrometer System (LC/MS/MS) provides exquisite selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT Workstation running MassLynx and QuanLynx software. As a result of high demand for LC/MS/.MS services, a second triple quadrupole tandem mass spectrometer (Waters Premier XE) was recently obtained to increase our capabilities. The front-end on the Premier XE is a Waters Agility Ultra-high Pressure Liquid Chromatograph (UPLC) that allows us to maximize sensitivity and minimize run-times, thereby increasing throughput. Like the Quattro Ultima, instrument control and data analysis on the Premier XE is performed with MassLynx and QuanLynx software. In addition, MetaboLynx software was purchased to aid in metabolite identification.

Pricing

Pricing

Prices and availability vary. PleaseContact Usfor current information.
 
If you are a City of Hope employee, please visitthis core facility's intranet sitefor pricing.
 

Analytical Pharmacology Team

Analytical Pharmacology Team

Contact Us

Contact Us

Edward Newman, Ph.D.
Co-director
626-256-HOPE (4673)
enewman@coh.org
 
Timothy W. Synold, Pharm.D.
Co-director
626-256-HOPE (4673)
tsynold@coh.org
 
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000
 
Shapiro Building
Room 1042
Phone: 626-256-HOPE (4673), ext. 62110
Fax: 626-301-8898
 
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti
800-888-5323
dgrignetti@coh.org

 

For sponsorships inquiries please contact:

Stefanie Sprester
213-241-7160
ssprester@coh.org

Christine Nassr
213-241-7112
cnassr@coh.org

 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 
NEWS & UPDATES
  • Ryan Chavira was a senior in high school when she began feeling sluggish, fatigued and, well, “down.” Trips to the doctor ended in “you’re fine” pronouncements; blood tests results showed nothing of real concern. But Chavira’s grandmother had passed away from ovarian cancer when she was in eig...
  • Brain tumors are exceptionally difficult to treat. They can be removed surgically, but individual cancer cells may have already spread elsewhere in the brain and can escape the effects of both radiation and chemotherapy. To prevent tumors from recurring, doctors need a way to find and stop those invasive cancer...
  • Breast cancer risk is personal; breast cancer risk assessment should be, too. To that end, City of Hope researchers have developed a starting point to help women (and their doctors) with a family history of the disease begin that risk assessment process. The result is an iPhone app, called BRISK, for Breast Can...
  • When it comes to breast cancer, women aren’t limited to getting screened and, if diagnosed, making appropriate treatment choices. They can also take a proactive stance in the fight against breast cancer by understanding key risk factors and practicing lifestyle habits that can help reduce their own breast...
  • Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone...
  • Genetics, genes, genome, genetic risk … Such terms are becoming increasingly familiar to even nonresearchers as studies and information about the human make-up become more extensive and more critical. At City of Hope, these words have long been part of our vocabulary. Researchers and physicians are studyi...
  • Mammograms are currently the best method to detect breast cancer early, when it’s easier to treat and before it’s big enough to feel or cause symptoms. But recent mammogram screening guidelines may have left some women confused about when to undergo annual testing. Here Lusi Tumyan, M.D., chief of t...
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...